Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
- Status
- UNKNOWN
- Phase
- PHASE2
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
- Status
- COMPLETED
- Phase
- PHASE1
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- Status
- TERMINATED
- Phase
- PHASE2
De-Escalation Therapy for Human Papillomavirus Negative Disease
- Status
- COMPLETED
- Phase
- PHASE2
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2